A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Latest Information Update: 09 Jun 2025
At a glance
- Drugs SGNPDL 1V (Primary)
- Indications Advanced breast cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Seagen
Most Recent Events
- 03 Jun 2025 Planned End Date changed from 4 Sep 2027 to 8 Apr 2028.
- 03 Jun 2025 Planned primary completion date changed from 4 Sep 2026 to 9 Apr 2027.
- 18 May 2025 Planned End Date changed from 17 Nov 2028 to 4 Sep 2027.